Determination of Finasteride in Human Plasma by HPLC-MS

    June 2003 in “ PubMed ”
    Xiang-Yang Li, Li Ding, Li Li, Xin Hao, Zhengxing Zhang
    TLDR The two finasteride formulations are bioequivalent.
    The study aimed to develop an HPLC-MS assay for determining finasteride in human plasma and assess the bioequivalence of two formulations in 20 healthy volunteers. The method involved plasma extraction with ethyl acetate and separation using a C18 column, with LC-ESI-MS performed in SIM mode. Calibration curves were linear from 1-200 micrograms.L-1, with a detection limit of 0.05 microgram.L-1 and recovery rates between 85.9%-98.7%. The analysis showed no significant difference in AUC and Cmax between the formulations, confirming their bioequivalence. The assay was sensitive, accurate, and convenient.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Feel like I'm a reasonably good responder

      in Is this regrowth?  274 upvotes 1 year ago
      The user "OP" reported significant hair regrowth using oral finasteride, oral and topical minoxidil, ketoconazole shampoo, and derma stamping. OP experienced initial shedding but no other side effects.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  43 upvotes 6 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Recovery from 2nd Dutasteride shed

      in Update  22 upvotes 1 year ago
      User switched from finasteride to dutasteride due to shedding, experienced two sheds, and now uses 5mg oral minoxidil, 0.5mg dutasteride, and 3ml oral castor oil daily. Hair has recovered from the second shed, and the user plans to maintain the current treatment.

      community I spoke to the Guy who did the Ru58841 (PSK-3841) research

      in Research/Science  290 upvotes 4 years ago
      The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

    Related Research

    2 / 2 results